Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients - A systematic review

被引：5
作者：
Simons, Martijn [1 ,2 ]
Ramaekers, Bram [1 ]
Peeters, Andrea [1 ]
Mankor, Joanne [3 ]
Paats, Marthe [3 ]
Aerts, Joachim [3 ]
van Harten, Wim [4 ,5 ]
Retel, Valesca [4 ,5 ]
Joore, Manuela [1 ,2 ]
机构：
[1] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, P Debyelaan 25, NL-6229 HX Maastricht, Netherlands
[2] Maastricht Univ, Care & Publ Hlth Res Inst CAPHRI, Univ Singel 40, NL-6229 ER Maastricht, Netherlands
[3] Erasmus MC, Dept Pulm Med, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[4] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Psychosocial Res & Epidemiol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[5] Univ Twente, Dept Hlth Technol & Serv Res, Hallenweg 5, NL-7522 NH Enschede, Netherlands
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2020年 / 153卷
关键词：
Non-small cell lung cancer; Targeted therapies; Immunotherapies; Survival analysis; Overall survival; RANDOMIZED PHASE-III; OPEN-LABEL; 1ST-LINE TREATMENT; CARBOPLATIN-PACLITAXEL; COMPARING GEFITINIB; CHEMOTHERAPY; ERLOTINIB; DOCETAXEL; ADENOCARCINOMA; MULTICENTER;
D O I：
10.1016/j.critrevonc.2020.103035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Outcomes used for the effectiveness (median) and cost-effectiveness (mean) on overall survival (OS) are different and can vary from one another. Therefore, we compared median and mean OS gains of targeted therapies and immunotherapies for stage IIIB/IV Non-small cell lung cancer and explored underlying aspect. Eligible trials were searched in PubMed, survival curves were digitized, and parametric survival models fitted to model the mean OS. Twenty-seven trials were found for targeted therapies (n = 17) and immunotherapies (n = 10). Differences between median and mean OS gains in months ranged from - 2.8 to 6.8 and - 4.9 to 0.3 for two different subgroups of targeted therapies, and -2.4 to 11.4 for immunotherapies. The mean OS gain was substantially larger for most immunotherapy trials, due to relatively long survival. Median and mean OS gains did not differ for targeted therapies. Our findings imply a potential discrepancy between the estimates of effectiveness and cost-effectiveness of cancer treatments.
引用
收藏
页数：12
相关论文
共 50 条
  • [41] Real-world effectiveness of immunotherapies in pre-treated, advanced non-small cell lung cancer Patients: A systematic literature review
    Juarez-Garcia, Ariadna
    Sharma, Ruchika
    Hunger, Matthias
    Kayaniyil, Sheena
    Penrod, John R.
    Chouaid, Christos
    LUNG CANCER, 2022, 166 : 205 - 220
  • [42] Impact of Opioid Use on Duration of Therapy and Overall Survival for Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
    Young, Philip
    Elghawy, Omar
    Mock, Joseph
    Wynter, Emmett
    Gentzler, Ryan D.
    Martin, Linda W.
    Novicoff, Wendy
    Hall, Richard
    CURRENT ONCOLOGY, 2024, 31 (01) : 260 - 273
  • [43] Molecularly-targeted therapies for non-small cell lung cancer
    Ramalingam, S
    Belani, CP
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (15) : 2667 - 2679
  • [44] Gefitinib or Erlotinib as Maintenance Therapy in Patients with Advanced Stage Non-Small Cell Lung Cancer: A Systematic Review
    Chen, Xiaofeng
    Liu, Yiqian
    Roe, Oluf Dimitri
    Qian, Yingying
    Guo, Renhua
    Zhu, Lingjun
    Yin, Yongmei
    Shu, Yongqian
    PLOS ONE, 2013, 8 (03):
  • [45] New Target Therapies in Advanced Non-Small Cell Lung Cancer: A Review of the Literature and Future Perspectives
    de Mello, Ramon Andrade
    Neves, Nathalia Moises
    Tadokoro, Hakaru
    Amaral, Giovanna Araujo
    Castelo-Branco, Pedro
    Zia, Victor Andre de Almeida
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 20
  • [46] Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer (Review)
    Antonelli, Giovanna
    Libra, Massimo
    Panebianco, Vincenzo
    Russo, Alessia Erika
    Vitale, Felice Vito
    Colina, Paulo
    D'Angelo, Alessandro
    Rossello, Rosalba
    Ferrau, Francesco
    ONCOLOGY LETTERS, 2016, 11 (01) : 3 - 8
  • [47] Erlotinib versus Pemetrexed for Pretreated Non-Squamous Non-Small Cell Lung Cancer Patients in Clinical Practice
    Zugazagoitia, J.
    Puente, J.
    Gonzalez-Larriba, J. L.
    Manzano, A.
    Sotelo, M.
    Hernandez, S.
    Sanz, J.
    Perez, P.
    Diaz-Rubio, E.
    ONCOLOGY, 2013, 84 (05) : 255 - 264
  • [48] A systematic review of targeted agents for non-small cell lung cancer
    Vestergaard, Hannah H.
    Christensen, Marcus R.
    Lassen, Ulrik N.
    ACTA ONCOLOGICA, 2018, 57 (02) : 176 - 186
  • [49] Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents
    Meoni, Giulia
    Cecere, Fabiana Letizia
    Lucherini, Elisa
    Di Costanzo, Francesco
    JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (03) : 282 - 290
  • [50] Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis
    Sohn, H. S.
    Kwon, J. -W.
    Shin, S.
    Kim, H. -S.
    Kim, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2015, 40 (06) : 661 - 671
12345